Swiss National Bank Uro Gen Pharma Ltd. Transaction History

Swiss National Bank

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 09, 2022	SELL	$5.12 - $8.74 $245,248 - $418,646	-47,900 Closed	0 $0
Q1 2022 May 09, 2022	BUY	$5.92 - $9.73 $23,680 - $38,920	4,000 Added 9.11%	47,900 $417,000
Q2 2021 Aug 06, 2021	BUY	$15.2 - $20.94 $21,280 - $29,316	1,400 Added 3.29%	43,900 $670,000
Q3 2020 Nov 09, 2020	BUY	$18.81 - $26.42 $50,787 - $71,334	2,700 Added 6.78%	42,500 $820,000
Q2 2020 Aug 05, 2020	BUY	$16.5 - $29.7 $87,450 - $157,410	5,300 Added 15.36%	39,800 $1.04 Million
Q1 2020 May 08, 2020	BUY	$13.68 - $34.6 $6,840 - $17,300	500 Added 1.47%	34,500 $615,000
Q4 2019 Feb 06, 2020	BUY	$21.11 - $34.86 $8,444 - $13,944	400 Added 1.19%	34,000 $1.14 Million
Q3 2019 Nov 12, 2019	BUY	$23.83 - $36.44 $33,362 - $51,016	1,400 Added 4.35%	33,600 $801,000
Q1 2019 May 10, 2019	BUY	$35.47 - $54.55 $496,580 - $763,700	14,000 Added 76.92%	32,200 $1.19 Million
Q4 2018 Feb 13, 2019	BUY	$38.35 - $50.39 $38,350 - $50,390	1,000 Added 5.81%	18,200 $784,000
Q2 2018 Aug 09, 2018	BUY	$48.35 - $65.33 $831,620 - $1.12 Million	17,200 New	17,200 $856,000

120

39.3M

158K

161K

Ticker URGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 22,740,500
Market Cap $282M
Description
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead...

Get notified when there are updates to the investment portfolio of Swiss National Bank, based on Form 13F filings with the SEC.

Stay updated on Swiss National Bank with notifications on news.